MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Urinary Symptoms and Parkinson’s Disease: The Patient’s Perspective

J. Wertheimer, B. Reynolds, C. Walton, J. McNamara, T. Hamran, S. Freedland (Los Angeles, CA, USA)

Meeting: MDS Virtual Congress 2020

Abstract Number: 793

Keywords: Non-motor Scales, Parkinsonism, Urinary dysfunction pharmacological management of

Category: Parkinson's Disease: Non-Motor Symptoms

Objective: To learn about prevalence rates and the impact of urinary symptoms on day-to-day function and quality of life from the patient’s perspective.

Background: Urinary dysfunction for individuals with Parkinson’s disease (PD) is highly prevalent. Urinary symptoms can be related to age, disease duration, and neurological disability. Greater insights from the patient’s perspective about the relationship between urinary symptoms, day-to-day living, and quality of life across disease duration and age cohorts are needed.

Method: A survey-based, cross sectional research design was used. 960 individuals with PD participated. Average age: 71.14 (SD: 8.16). Average disease duration: 10.5 years (SD: 7.25). Instruments: The Parkinson Alliance Demographic Questionnaire, American Urological Association Symptom Score Questionnaire (AUA-7), and Health Related Quality of Life Measure (EQ-5D-5L).

Results: Eighty-five percent of the sample reported urinary symptoms. Storage symptoms (nocturia, urination frequency, urination urgency) were more prevalent than voiding symptoms (incomplete emptying, urinary intermittence, weak urinary stream, hesitation). Urinary urgency was most bothersome, followed by urinary frequency and nocturia. Disease duration impacted incomplete emptying, weak stream, and nocturia. Nocturia was reported in greater frequency for the Older PD group (>70 years) as compared to the Younger PD group (<70 years). Nocturia, urgency, and incontinence had the most interference in daily activities; 1/3 of the participants reported major interference. Due to urinary symptoms: 27% of the participants reported moderate to extreme altered interest in social activities; 34% reported moderate to extreme embarrassment; 22% reported moderate to extreme isolation. Emotional status was significantly related to urinary symptoms. 27% rated their level of depression or anxiety as moderate to severe. 62% of the sample reported good to excellent QOL; 37% reported poor to fair QOL; <1% reported worst imaginable QOL. 41% reported that QOL was somewhat to extremely impacted by urinary symptoms.

Conclusion: Urinary symptoms were highly prevalent for individuals with PD. Urinary symptom profiles were observed for disease duration and age cohorts. Urinary symptoms impacted engagement in daily activities and had a significant relationship with emotional status and QOL. Implications for treatment providers are discussed.

References: Araki I, Kuno S. Assessment of voiding dysfunction in Parkinsonís disease by the International Prostate Symptom Score. J Neurol Neurosurg Psychiatry 2000;68:429ñ433. Barone, P., Antonini, A., Colosimo, C. et al, The Priamo study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. MovDisord. 2009;24:1641–1649 Chai T C, Steers WD. Neurophysiology of micturition and continence . Urol Clin N Am 1996;23:221ñ223. The EuroQol Group (1990). EuroQol — a new facility for the measurement of health- related quality of life. Health Policy 16(3), 199-208 Margolesky, J., Bette, S., Singer, C. (2020). Management of Urologic and Sexual Dysfunction in Parkinson Disease. Clinics in Geriatric Medicine, 36 (1), 69 – 80. McDonald, C., Winge, K., Burn, D.J. Lower urinary tract symptoms in Parkinson’s disease: Prevalenc, aetiology and management. Parkinsonism RelatDisord. 2017;35:8–16 Sakakibara R, Panicker J, Finazzi-agro E, Iacovelli V, Bruschini H. (2016). A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn.35(5):551-63. doi:10.1002/nau.22764 Weinberger MW. Differential diagnosis of urinary incontinence. In Ostergard DR, Bent AE. Urogynecology and urodynamics, theory and practice. Baltimore: Williams & Wilkins, 1996:83-89. Yeo L, Singh R, Gundeti M, Barua JM, Masood J. (2012). Urinary tract dysfunction in Parkinson’s disease: a review. Int Urol Nephrol, 44(2):415-24.

To cite this abstract in AMA style:

J. Wertheimer, B. Reynolds, C. Walton, J. McNamara, T. Hamran, S. Freedland. Urinary Symptoms and Parkinson’s Disease: The Patient’s Perspective [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/urinary-symptoms-and-parkinsons-disease-the-patients-perspective/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/urinary-symptoms-and-parkinsons-disease-the-patients-perspective/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley